Loading current stock analysis…
Loading current stock analysis…
India
Reported ownership for FY2027-Q2 as of 2026-09-30.
As of 06 Nov 2026, 03:30 pm
Eris Lifesciences is seeking shareholder approval via postal ballot to appoint Mr. Akhil Awasthi as a Non-Executive Independent Director for five consecutive years, from September 26, 2026, to September 25, 2031. Remote e-voting was active from November 6, 2026, to December 5, 2026.
As of November 6, 2026, the stock closed at ₹1,237.0 with a market capitalization of approximately ₹17,044 crore. It posted a +12.9% return over 10 days and +4.4% over one month, but remains down -17.6% year-to-date and -22.0% over the past year.
The nearest support level is ₹1,228.6 (0.68% below), followed by ₹1,220.37. Resistance is located at ₹1,242.1 (0.41% above) and ₹1,254.3 (1.40% above). The daily trend indicator shows a bullish supertrend direction, while the weekly trend indicates bearish momentum.
Eris will host the 'Eris Investor Meet - 2026' on Thursday, November 19, 2026, in Mumbai. The event will be available in both physical and virtual modes, with discussions restricted to publicly available documents.
As of 06 Nov 2026, 03:30 pm
Recent drawdown or price variability is materially high and may lead to larger short-term outcomes.
Primary driver: Price remains materially below a previous peak
Upward price movement of 2.79 standard deviations recorded on 2026-11-06.
Unusual market activity that may warrant review of the underlying price, volume, or news context.
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Latest complete financial results for Q2 FY27 and comparative quarterly trends.
| Metric | Q2 FY26 | Q1 FY27 | Q2 FY27(Latest) |
|---|---|---|---|
| Income | ₹795 crore | ₹876 crore | PEAK₹896 crore |
| Expenses | ₹623 crore | ₹696 crore | PEAK₹703 crore |
| Finance Costs | PEAK₹49.6 crore | ₹46.7 crore | ₹46.4 crore |
| Other Expenses | ₹164 crore | ₹184 crore | PEAK₹208 crore |
| Profit Before Exceptional Items And Tax | ₹172 crore | ₹180 crore | PEAK₹193 crore |
| Profit Before Tax | ₹172 crore | PEAK₹180 crore | ₹157 crore |
| Profit Loss For Period From Continuing Operations | ₹134 crore | ₹144 crore | PEAK₹188 crore |
| Tax Expense | PEAK₹38.2 crore | ₹36.2 crore | -₹31.2 crore |
Revenue from operations rose 12.6% year on year to ₹892 crore in the quarter ended 30 September 2026, while profit before exceptional items and tax increased 11.8% to ₹193 crore. A ₹35.9 crore exceptional charge pulled profit before tax down 9.0% year on year, but a net tax benefit supported profit for the period of ₹187 crore and basic EPS of ₹13.26.
Revenue and pre-exceptional profit grew year on year, but the exceptional charge drove reported profit before tax lower. The net tax benefit lifted reported earnings and EPS, while cash balances increased and the borrowing mix shifted toward current borrowings as noncurrent borrowings fell.
Exchange disclosures and regulatory announcements for Eris Lifesciences.
Eris Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
Eris Lifesciences Limited is seeking shareholder approval by special resolution to appoint Mr. Akhil Awasthi (DIN: 00148350) as a Non-Executive Independent Director for five consecutive years, from September 26, 2026 to September 25, 2031. He was appointed as an Additional Director effective September 26, 2026, subject to member approval. The company issued the postal ballot notice dated November 4, 2026; remote e-voting runs from 9:00 a.m. IST on November 6, 2026 to 5:00 p.m. IST on December 5, 2026. The appointment has not yet been approved by shareholders in this filing.
Eris Lifesciences Limited has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot |SUBJECT: Notice Of Shareholders Meetings-XBRL
Eris Lifesciences Limited has notified the BSE and NSE that the transcript of the Analyst and Investor Call, held following the announcement of financial results for the quarter and half-year ended September 30, 2026, is available on its website. The filing was signed by Company Secretary Milind Talegaonkar on October 29, 2026.
Eris Lifesciences Limited will host “Eris Investor Meet - 2026” on Thursday, November 19, 2026, in Mumbai in physical and virtual modes, for a group of investors and analysts. The company stated that the schedule is indicative and that discussions would refer to publicly available documents, with no unpublished price sensitive information intended to be discussed.
Eris Lifesciences Limited’s Board of Directors approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026, on October 26, 2026. The consolidated net profit was Rs 187.14 Crores (Q) and Rs 330.46 Crores (H1), with revenue from operations of Rs 892.37 Crores (Q) and Rs 1,765.62 Crores (H1). Key substantive events included the effective amalgamation/demerger scheme between Aprica Healthcare Limited, Eris Oaknet Healthcare Private Limited, and Eris Therapeutics Limited (effective Oct 22, 2026), resulting in a Rs 96 Crore current tax credit; recognition of Rs 17.24 Crores exceptional item due to New Labour Codes; and completion of the acquisition of Branded Probiotics Business from Velbiom Probiotics Private Limited for Rs 50 Crores. Walker Chandiok & Co LLP issued unmodified limited review reports.
Eris Lifesciences Limited filed an investor presentation with the NSE and BSE on October 26, 2026, detailing financial results for Q2 and H1 FY27. The company reported consolidated revenue growth of 12.6% YoY in Q2 to ₹892 Cr, with PAT increasing 39.2% to ₹187 Cr (Adjusted PAT ₹158 Cr). In its Domestic Branded Formulations (DBF) segment, revenue grew 14.1% YoY to ₹809 Cr in Q2, though EBITDA margin contracted by 191 bps to 35.7%. Key operational updates include a merger order from the NCLT between subsidiaries Aprica, Eris Oaknet, and ETL, generating a positive tax impact of ₹65 Cr; the commercialization of the Bhopal facility for insulin vials and cartridges; and the licensing of injectable brands to Zorvia Healthcare for a 7% royalty. Additionally, the company received regulatory approval for Phase 1 and Phase 3 trials for India’s first Recombinant Semaglutide.
Integrated Filing- Financials|Original|
Recent market and company developments associated with Eris Lifesciences.
Eris Lifesciences expects profitability to improve as biologics production ramps up and acquired businesses continue to scale. The company also expects India's semaglutide market to grow significantly over the next year while planning faster debt reduction as its capex cycle slows.
Buy Eris Lifesciences; target of Rs 1500: Prabhudas Lilladher Follow Us On: Stocks: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Others Trending Topics more Sensex Today Jio IPO Allotment Jio IPO Listing Date Israel Elections 2026 live Microsoft Buyout news Gyanesh Kumar Benjamin Netanyahu Noel Tata Ather Share Price Anthropic IPO News more Business Markets Stocks India News City News Economy Mutual Funds Personal Finance IPO News Startups Markets more Home Currencies Commodities Pre-Market IPO Global Market US Markets Bonds Silver MCX Price Gold MCX Price Personal Finance more Home Loa
Honasa Consumer Ltd notched up volume of 196.48 lakh shares by 14:14 IST on NSE, a 26.53 fold spurt over two-week average daily volume of 7.41 lakh shares
Here’s why ChrysCapital expects 20-25% of the latest $2.2-billion fund to go to pharma, healthcare
Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance.
V Krishnakumar, Eris Lifesciences, Biological E, BE BioSol, Eris Lifesciences COO, Biological E CEO, CDMO business, biopharma, vaccine manufacturers, pharma leadership, Krishnakumar resignation, Eris Lifesciences resignation
Private equity firm ChrysCapital is set to acquire a significant stake in Linux Laboratories. This deal will see existing investor Tata Capital Healthcare Fund exit its entire holding. Linux Laboratories focuses on central nervous system therapies and has a strong brand portfolio. The company anticipates robust revenue and Ebitda growth in the coming years. This acquisition highlights continued private equity interest in India's pharmaceutical sector.
Sensex, Nifty, Share Prices LIVE: Sensex was up 160.95 pts or 0.20% to 78,741.95 at 9.16 am after opening at 78,782.43 from the previous close of 78,581; Nifty inched up 8.70 pts or 0.04% to 24,633.35.
Comprehensive Section Breakdown for Eris Lifesciences
Strategic Vision: Pharmaceutical company developing and marketing branded formulations for chronic diseases.
• Vertically integrated pharmaceutical operations with WHO-GMP approved manufacturing facilities.
• Extensive distribution network across India.
• Strategic acquisitions to expand into new therapeutic areas and product segments.
Revenue from operations increased 2.2% sequentially from ₹873 crore in Q1 FY2026-27 to ₹892 crore in Q2. Other income of ₹3.2 crore brought total income to ₹896 crore. Expenses rose 1.0% sequentially to ₹703 crore, slower than revenue; within this, other expenses increased 12.9% to ₹208 crore, while finance costs edged down to ₹46.4 crore.
Profit before exceptional items and tax was ₹193 crore, up 7.1% from Q1 FY2026-27 and 11.8% from Q2 FY2025-26. This indicates growth in pre-exceptional earnings even as the exceptional charge weighed on reported pre-tax profit.
The ₹35.9 crore exceptional charge, with no exceptional item in Q1 FY2026-27 or Q2 FY2025-26, reduced profit before tax to ₹157 crore. Profit before tax was down 12.8% sequentially and 9.0% year on year.
Tax was a net benefit of ₹31.2 crore, compared with an expense of ₹36.2 crore in Q1 FY2026-27. The quarterly tax line comprised a current tax benefit of ₹64.8 crore, partly offset by deferred tax expense of ₹33.6 crore. Profit from continuing operations was ₹188 crore; total profit for the period was ₹187 crore, of which ₹183.8 crore was attributable to owners of the parent and ₹3.3 crore to non-controlling interests.
Basic EPS was ₹13.26, compared with ₹10.28 in Q1 FY2026-27 and ₹8.82 in Q2 FY2025-26. The sequential increase in reported profit and EPS came alongside lower profit before tax, reflecting the net tax benefit.
Operating cash flow was ₹637 crore in Q2 FY2026-27, while investing and financing activities recorded outflows of ₹285 crore and ₹169 crore, respectively. Reported free cash flow was ₹352 crore.
Cash and cash equivalents stood at ₹238 crore on 30 September 2026, up from ₹54.7 crore on 31 March 2026. Over the same dates, noncurrent borrowings declined to ₹427 crore from ₹956 crore, while current borrowings increased to ₹1,954 crore from ₹1,354 crore. Equity attributable to owners of the parent rose to ₹4,144 crore from ₹3,903 crore.
Management said brands contributing about ₹100 crore of sales were out-licensed to Zorvia Healthcare, with Eris retaining brand ownership and earning a 7% royalty. Excluding those brands, Q2 Domestic Branded Formulations revenue growth was 16.5%, compared with reported growth of 14.1%. DBF EBITDA margin was 35.7%, down from 37.6%, a decline of 191 basis points. Management expects the out-licensed portfolio to contribute roughly 100 basis points of gross margin improvement going forward.
Category: Pharmaceuticals
Focuses on addressing chronic and sub-chronic diseases, with a core presence in the cardio-metabolic therapeutic area.
Category: Pharmaceuticals
Includes oral anti-diabetic medications and insulin products.
Category: Pharmaceuticals
Products aimed at managing cardiovascular health.
Category: Pharmaceuticals
Nutritional supplements and products.
Category: Pharmaceuticals
Expanding into dermatology, gynaecology, neuroscience, nephrology, oncology, and critical care.
Category: Pharmaceuticals
Segment includes sterile injectables, acquired through Swiss Parenterals, and branded injectables in critical care.
Category: Pharmaceuticals
Entry into the oncology segment with a portfolio of monoclonal antibodies.
Core Thesis: The company engages with the market through patient care initiatives and India-centric studies to support physician management of patient health.
• Patient Care Initiatives (PCI): This platform delivers advanced diagnostic and monitoring technologies to patients, providing insights to support physicians in managing health outcomes. • India-Centric Studies: The company conducts studies to generate and utilize India-specific data relevant to the diagnosis and management of cardio-metabolic conditions.